Top Markets
Coin of the day
Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT
株式のランク #20725
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
株価
$0.5194
時価総額
$125.72M
変化(1日)
-0.12%
変化(1年)
48.40%
US
取引 Vaxart, Inc. (VXRT)

カテゴリー

Vaxart, Inc.(VXRT)の配当利回りの履歴
Vaxart, Inc.(銘柄コード: VXRT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Vaxart, Inc.(VXRT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)